GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovotech Inc (TSXV:IOT) » Definitions » EV-to-FCF

Innovotech (TSXV:IOT) EV-to-FCF : -47.27 (As of Apr. 07, 2025)


View and export this data going back to 2003. Start your Free Trial

What is Innovotech EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Innovotech's Enterprise Value is C$6.48 Mil. Innovotech's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was C$-0.14 Mil. Therefore, Innovotech's EV-to-FCF for today is -47.27.

The historical rank and industry rank for Innovotech's EV-to-FCF or its related term are showing as below:

TSXV:IOT' s EV-to-FCF Range Over the Past 10 Years
Min: -8371.3   Med: -9.09   Max: 1061.25
Current: -47.27

During the past 13 years, the highest EV-to-FCF of Innovotech was 1061.25. The lowest was -8371.30. And the median was -9.09.

TSXV:IOT's EV-to-FCF is ranked worse than
100% of 460 companies
in the Biotechnology industry
Industry Median: 2.335 vs TSXV:IOT: -47.27

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-07), Innovotech's stock price is C$0.135. Innovotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was C$-0.008. Therefore, Innovotech's PE Ratio (TTM) for today is At Loss.


Innovotech EV-to-FCF Historical Data

The historical data trend for Innovotech's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovotech EV-to-FCF Chart

Innovotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.36 50.62 -200.57 34.84 -10.19

Innovotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.46 -10.19 -15.93 -10.48 -47.27

Competitive Comparison of Innovotech's EV-to-FCF

For the Biotechnology subindustry, Innovotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovotech's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovotech's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Innovotech's EV-to-FCF falls into.


;
;

Innovotech EV-to-FCF Calculation

Innovotech's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=6.476/-0.137
=-47.27

Innovotech's current Enterprise Value is C$6.48 Mil.
Innovotech's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovotech  (TSXV:IOT) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Innovotech's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.135/-0.008
=At Loss

Innovotech's share price for today is C$0.135.
Innovotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.008.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Innovotech EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Innovotech's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovotech Business Description

Traded in Other Exchanges
N/A
Address
2011 - 94 Street, Suite L131, Edmonton, AB, CAN, T6N 1H1
Innovotech Inc is a Canada-based company that provides solutions to client biofilm problems through its biofilm contract research department. The core activities of the company are sales of its products, conducting contract research for outside customers, and research and development to identify products for future commercialization. The products of the company include human and fungal biofilm susceptibility tests, a seed treatment designed to combat bacterial and fungal diseases, and an assay used in growing microbial biofilms for research purposes. Geographically, the firm has a business presence in the United States, Canada, and the Rest of the world of which the majority of the revenue is derived from the United States.
Executives
James Gregory Timourian Senior Officer
Bradley Alan Clark Director
Alan Clyde Hayes Savage 10% Security Holder
Craig Milne Director
David Shong-tak Tam Director
Bernard Grobbelaar Director